Metabolic Collaboration and Licensing Deals 2019-2026

Description

The definitive benchmark for metabolic dealmaking

Metabolic partnering spans a range of large, chronic disease indications, with deal structures reflecting long-term treatment paradigms, significant commercial potential, and evolving innovation across the space.

This report provides a comprehensive and structured analysis of 639 metabolic collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how metabolic deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by stage, asset type, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a high-value and commercially driven therapeutic landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within metabolic partnerships, particularly in areas driven by large patient populations and long-term treatment dynamics.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark live transactions
Prepare for negotiations with well-defined market context
Evaluate partnership opportunities and counterparties
Support internal strategy with robust, defensible data
What's included
639 metabolic collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, therapy, and technology)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for metabolic dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how metabolic partnerships are structured, negotiated, and valued.

Product Code: CP2205

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in metabolic dealmaking

2.1. Introduction
2.2. Metabolic partnering over the years
2.3. Metabolic partnering by deal type
2.4. Metabolic partnering by industry sector
2.5. Metabolic partnering by stage of development
2.6. Metabolic partnering by technology type
2.7. Metabolic partnering by therapeutic indication

Chapter 3 - Financial deal terms for metabolic partnering

3.1. Introduction
3.2. Disclosed financials terms for metabolic partnering
3.3. Metabolic partnering headline values
3.4. Metabolic deal upfront payments
3.5. Metabolic deal milestone payments
3.6. Metabolic royalty rates

Chapter 4 - Leading metabolic deals and dealmakers

4.1. Introduction
4.2. Most active in metabolic partnering
4.3. List of most active dealmakers in metabolic
4.4. Top metabolic deals by value

Chapter 5 - Metabolic contract document directory

5.1. Introduction
5.2. Metabolic partnering deals where contract document available

Chapter 6 - Metabolic dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by metabolic therapeutic target
Deal directory
Deal directory - Metabolic deals by company A-Z
Deal directory - Metabolic deals by technology type
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Metabolic partnering since 2019
Figure 2: Metabolic partnering by deal type since 2019
Figure 3: Metabolic partnering by industry sector since 2019
Figure 4: Metabolic partnering by stage of development since 2019
Figure 5: Metabolic partnering by technology type since 2019
Figure 6: Metabolic partnering by indication since 2019
Figure 7: Metabolic deals with a headline value
Figure 8: Metabolic deals with upfront payment values
Figure 9: Metabolic deals with milestone payment
Figure 10: Metabolic deals with royalty rates
Figure 11: Active metabolic dealmaking activity since 2019
Figure 12: Top metabolic deals by value since 2019